Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor

X
Trial Profile

Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor

Status: Not yet recruiting
Phase of Trial: Phase 0

Latest Information Update: 17 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TAA6 chimeric antigen receptor T cell therapy PersonGen BioTherapeutics (Primary)
  • Indications Gastric cancer; Lung cancer; Neuroblastoma; Osteosarcoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors PersonGen Biotherapeutics
  • Most Recent Events

    • 05 Jul 2022 According to PersonGen Biotherapeutics media release, the Center for Drug Evaluation (CDE) of NMPA has cleared the companys Investigational New Drug (IND) application for TAA06, for the treatment of R/R Neuroblastoma.
    • 05 May 2021 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top